Pelvic & Abdominal Pain Treatment in Birmingham & Bessemer, AL

Pelvic & Abdominal Pain Treatment at Alabama Pain Physicians

Chronic pelvic and abdominal pain can be frustrating — especially when tests come back normal and no one can find the cause. Our physicians specialize in identifying and treating the pain sources that other specialists may miss.

Your treatment plan may include:

• Medical management — neuropathic pain medications, visceral pain-specific treatments, and medication optimization
• Superior hypogastric plexus blocks — targeting the nerve network responsible for pelvic pain
• Ganglion impar blocks — for coccydynia, perineal pain, and rectal pain
• Celiac plexus blocks — for upper abdominal and visceral pain
• Trigger point injections — for abdominal wall myofascial pain, a commonly missed diagnosis
• Nerve blocks — ilioinguinal, iliohypogastric, and pudendal nerve blocks for specific pelvic pain patterns
• Spinal cord stimulation — for chronic, refractory pelvic pain
• Medical marijuana certification — for qualifying patients with chronic pelvic or abdominal pain

Pelvic and abdominal pain often has multiple contributing sources. We take the time to evaluate all of them and build a treatment plan that addresses your specific pain.

Understanding Pelvic & Abdominal Pain: A Multi-System Perspective

The following publication by Ty Thomas, MD explores the deeper biological mechanisms behind chronic pelvic and abdominal pain. This research informs how we approach these complex cases at Alabama Pain Physicians.

Author’s Statement

I am a board-certified Physical Medicine and Rehabilitation physician with additional certification in Venous and Lymphatic Medicine. For over fifteen years at Alabama Pain Physicians, I have managed patients with chronic pelvic and abdominal pain — conditions that have often been evaluated by multiple specialists before reaching a pain practice. A typical patient has seen a gynecologist for endometriosis, a urologist for bladder pain, a gastroenterologist for irritable bowel symptoms, and a primary care physician who prescribed antidepressants when no single specialist could explain the totality of her symptoms. Each specialist treated their organ. No one evaluated the biology connecting all three.

The consistent observation that drives this publication is that chronic pelvic pain is not three separate organ diseases coincidentally occurring in the same patient. It is one multi-domain biological dysfunction manifesting across multiple pelvic organs through shared neural pathways, shared immune mechanisms, and a shared upstream driver that no single specialty evaluates: the gut-estrogen-immune axis. The gut microbiome regulates circulating estrogen through the estrobolome. Gut dysbiosis drives estrogen dominance, fuels systemic inflammation through LPS translocation, and impairs the immune clearance of ectopic endometrial tissue. These mechanisms connect what gynecology, urology, and gastroenterology treat as separate diseases into a single biological cascade.

These publications are my attempt to provide information about this understanding. They are not a claim to have found a root cause. They are a framework for asking better questions.

Abstract

Background

Chronic pelvic pain affects approximately 1 in 7 women in the United States, with a prevalence comparable to migraine, asthma, and chronic back pain (StatPearls, 2025). Endometriosis is present in 40–87% of women with chronic pelvic pain and affects 5–10% of reproductive-age women globally (PMC, 2024). Interstitial cystitis/painful bladder syndrome was diagnosed in up to 79% of women with persistent pelvic pain after hysterectomy for pelvic pain, suggesting it is frequently unrecognized (PMC, 2007). In more than half of chronic pelvic pain cases, comorbid conditions including endometriosis, pelvic adhesions, IBS, or interstitial cystitis coexist (StatPearls, 2025). Current management fragments these conditions across gynecology, urology, and gastroenterology, with each specialty treating its organ without evaluating the shared biological domains driving multi-organ pelvic dysfunction. Treatment options for chronic pelvic pain remain limited, with treatment typically targeting the suspected single etiology.

Methods

We conducted a narrative review of PubMed-indexed literature examining pelvic and abdominal pain through cellular systems theory. We reviewed evidence for viscerosomatic convergence, cross-organ sensitization, the estrobolome and gut-estrogen-immune axis, neurogenic inflammation, central sensitization, and neuroendocrine dysfunction in chronic pelvic pain conditions. We analyzed treatment response data and constructed composite clinical scenarios illustrating individualized multi-domain assessment.

Results

Published evidence demonstrates that pelvic and abdominal pain involves dysfunction across multiple biological domains through shared mechanisms: viscerosomatic convergence in the spinal cord means that visceral afferents from the uterus, bladder, and colon share second-order neurons, providing the anatomical basis for cross-organ sensitization; the estrobolome — the subset of gut microbial genes encoding estrogen-metabolizing enzymes — connects gut dysbiosis to estrogen dominance through increased β-glucuronidase activity and estrogen reabsorption; LPS translocation from a dysbiotic gut activates the TLR4/NF-κB pathway, impairs macrophage phagocytic clearance of ectopic endometrial tissue, and drives chronic inflammation; and cross-organ sensitization has been experimentally demonstrated between the bladder, colon, and uterus, providing a mechanistic basis for the clinical co-occurrence of endometriosis, interstitial cystitis, and IBS.

Conclusions

The pattern of multi-organ pelvic dysfunction with shared upstream biological drivers supports the hypothesis that chronic pelvic pain represents a multi-system cellular disorder that is artificially fragmented across medical specialties. Cellular systems theory provides a framework for evaluating the gut-estrogen-immune axis, visceral sensitization, and neuroendocrine dysfunction as an integrated biological system rather than as separate organ diseases.

1. Introduction

Chronic pelvic pain is a persistent, disabling, or cyclic intermittent pain within the pelvis that affects approximately 1 in 7 women in the United States (StatPearls, 2025). Its prevalence is comparable to that of migraine headaches, asthma, and chronic back pain. Many individuals endure pain for more than two years before seeking medical care. Chronic pelvic pain shares pathophysiological mechanisms, including central sensitization, with other chronic pain syndromes such as complex regional pain syndrome and fibromyalgia (StatPearls, 2025). In men, chronic pelvic pain may involve urogenital pain, erectile dysfunction, urinary symptoms, and emotional disturbances.

The clinical reality of chronic pelvic pain is one of diagnostic fragmentation. A woman with pelvic pain sees a gynecologist, who identifies endometriosis. The same woman has bladder urgency and pain, so she sees a urologist, who diagnoses interstitial cystitis. She also has bloating, alternating bowel habits, and abdominal cramping, so she sees a gastroenterologist, who diagnoses irritable bowel syndrome. She receives hormonal suppression from the gynecologist, bladder instillations from the urologist, and antispasmodics from the gastroenterologist. Each specialist treats their organ. The question no one asks is: why are three organs in the same anatomical compartment dysfunctional simultaneously? Is this coincidence, or is it one biological process manifesting across multiple organs?

Cellular systems theory proposes the latter. Chronic pelvic pain emerges from the dynamic interaction of gut-microbiome-mediated estrogen dysregulation, immune dysfunction, visceral neurogenic inflammation, cross-organ sensitization through shared spinal pathways, central sensitization, hormonal imbalance, and pelvic floor dysfunction. The uterus, bladder, and colon are not separate biological systems. They share neural pathways through viscerosomatic convergence in the dorsal root ganglia and spinal cord segments S2–S4 and T10–L1. They share immune regulation through the mucosal immune system. They share hormonal responsiveness to estrogen, progesterone, and cortisol. When the upstream biology — particularly the gut-estrogen-immune axis — is dysfunctional, all three organs become symptomatic. Treating one organ at a time, through one specialty at a time, without evaluating the shared biology produces the pattern that defines chronic pelvic pain: years of specialist visits, multiple diagnoses, partial treatments, and persistent suffering.

2. Methods

We conducted a narrative review of PubMed-indexed literature examining chronic pelvic and abdominal pain through cellular systems theory. Search terms included chronic pelvic pain, endometriosis, interstitial cystitis, painful bladder syndrome, irritable bowel syndrome, visceral pain, visceral hyperalgesia, viscerosomatic convergence, cross-organ sensitization combined with central sensitization, estrobolome, gut microbiome, estrogen metabolism, β-glucuronidase, LPS, TLR4, NF-κB, neurogenic inflammation, pelvic floor dysfunction, myofascial trigger points, HPA axis, and treatment response. We included systematic reviews, meta-analyses, mechanistic studies, and animal models demonstrating cross-organ sensitization. We constructed composite clinical scenarios illustrating individualized multi-domain assessment.

3. The Neuroanatomy of Pelvic Pain: Why Organs Cannot Be Separated

3.1 Viscerosomatic Convergence

The neuroanatomy of the pelvis makes organ-specific pain diagnosis inherently difficult and organ-specific treatment inherently incomplete. Visceral afferents — the sensory nerve fibers carrying pain signals from internal organs — constitute only 2–7% of all afferent fibers passing through each dorsal root ganglion (PMC, 2017). As a result, almost all spinal neurons that receive visceral input also receive somatosensory input from muscle and skin through viscerosomatic convergence. This convergence means that the brain cannot precisely distinguish whether a pain signal originated from the uterus, the bladder, the colon, or the pelvic floor muscles. It also explains referred pain — why uterine pathology can be felt as low back pain, why bladder inflammation produces suprapubic and perineal discomfort, and why bowel dysfunction generates lower abdominal wall pain.

Because visceral afferent fibers terminate over several spinal segments above and below their primary level of input, referred pain may appear in areas remote from the affected organ. A woman with endometriosis may report hip pain, inner thigh pain, or low back pain that has no musculoskeletal explanation because the visceral signals are being interpreted as somatic pain through convergent spinal pathways. This neuroanatomical reality means that the traditional diagnostic approach of matching the pain location to the organ directly beneath it systematically fails in pelvic pain.

3.2 Cross-Organ Sensitization

Cross-organ sensitization is the process by which pain in one visceral organ increases sensitivity to pain in another organ. It arises from the convergence of innervation from multiple pelvic organs in the dorsal root ganglia and on the same spinal cord segments (PMC, 2024). This cross-sensitization has been experimentally demonstrated in multiple organ combinations: bladder inflammation lowers the colorectal pain threshold to balloon distension; conversely, colonic inflammation produces bladder irritability and altered urinary function; and uterine inflammation produces signs of inflammation in both the colon and the bladder (Frontiers in Cellular Neuroscience, 2020; Cells, 2025).

Cross-organ sensitization provides the mechanistic basis for the clinical triad of endometriosis, interstitial cystitis, and irritable bowel syndrome co-occurring in the same patient at rates far exceeding chance. This is not three separate diseases. It is one sensitized pelvic neural network in which inflammation or dysfunction in any organ amplifies pain in every other organ sharing the same spinal segments. Treating endometriosis surgically without addressing the bladder sensitization and bowel dysfunction explains why so many women continue to experience pelvic pain after laparoscopic excision of endometriotic lesions. The surgical excision removes one nociceptive source without reversing the cross-organ sensitization that the source created.

4. Evidence for Multi-Domain Dysfunction in Pelvic and Abdominal Pain

4.1 The Estrobolome and Gut-Estrogen-Immune Axis

The estrobolome is the aggregate of genes in the gut microbiome capable of metabolizing estrogen. Gut bacteria produce β-glucuronidase, an enzyme that deconjugates estrogen metabolites in the intestine, converting them from their inactive conjugated form back to active estrogen, which is then reabsorbed into systemic circulation through the enterohepatic circulation (PMC, 2023; Frontiers in Microbiology, 2024). In a healthy gut with normal microbial diversity, this process is balanced and estrogen levels are appropriately regulated. In a dysbiotic gut, β-glucuronidase activity is increased, leading to excessive estrogen reabsorption and estrogen dominance.

Estrogen dominance is directly relevant to endometriosis because endometriotic lesions are estrogen-dependent — they require estrogen for growth, proliferation, and survival. Gut dysbiosis drives estrogen dominance through the estrobolome, fueling the growth of endometriotic tissue through a mechanism that gynecology does not evaluate because it lies outside the reproductive tract. This connection between the gut microbiome and endometriosis has been demonstrated in animal models: fecal transplant from mice with endometriosis restored lesion growth in microbiota-depleted mice, and butyrate (a short-chain fatty acid produced by healthy gut bacteria) curtailed endometriotic lesion growth (Frontiers in Microbiology, 2024). Specific bacterial strains including Lactobacillus and Bifidobacterium show promise in reducing endometriosis inflammation by strengthening the intestinal barrier and modulating estrogen metabolism (Frontiers in Microbiology, 2025).

4.2 LPS-TLR4-NF-κB: The Inflammatory Bridge

Gut barrier dysfunction allows bacterial lipopolysaccharide (LPS) to translocate into systemic circulation. LPS activates Toll-like receptor 4 (TLR4) on immune cells, triggering NF-κB-mediated inflammatory cascades that produce TNF-α, IL-6, IL-8, and other cytokines (Camilleri, Gut, 2019; Niederberger and Geisslinger, FASEB Journal, 2008). In endometriosis, this LPS-TLR4-NF-κB pathway has been shown to impair macrophage phagocytic function, reducing the immune system’s capacity to clear newly implanted ectopic endometrial tissue (Front Cell Infect Microbiol, 2024). This impaired immune clearance promotes lesion survival and growth. The pathway also promotes cell adhesion, proliferation, and anti-apoptosis in endometriotic tissue — directly connecting gut barrier dysfunction to endometriosis progression through immune mechanisms.

The same LPS-driven inflammatory cascade activates the urothelium of the bladder, contributing to the mucosal inflammation and barrier dysfunction that characterizes interstitial cystitis. It sensitizes visceral afferents in the colon, contributing to the visceral hypersensitivity of IBS. The single upstream event — gut barrier failure allowing LPS translocation — produces inflammatory activation across multiple pelvic organs simultaneously through the same TLR4/NF-κB pathway. This provides the biological explanation for why endometriosis, IC, and IBS co-occur: they share the same inflammatory driver.

4.3 Central Sensitization and Visceral Hyperalgesia

Chronic pelvic pain is now understood as a centralized pain condition in which the body develops a lower threshold for discomfort, often as a result of chronic visceral nociceptive input (StatPearls, 2025). In women with endometriosis, the acute pain associated with the condition can become centralized over a 3–6 month period, evolving into chronic pain that persists even after surgical removal of endometriotic lesions. In centralized pain, sensations that were previously mild to moderate may be perceived as severe (hyperalgesia), and even normal touch can be experienced as painful (allodynia). Cutaneous allodynia in dermatomal patterns corresponding to pelvic innervation segments has been documented in women with chronic pelvic pain, providing clinical evidence of central sensitization (PubMed, 2009).

Visceral hyperalgesia — an exaggerated pain response to normal visceral stimuli such as bladder filling or colonic distension — is the hallmark of both IBS and interstitial cystitis. It arises from peripheral sensitization of visceral afferents, cross-organ sensitization, and central amplification in which spinal cord neurons receiving continuous input from sensitized visceral afferents become more responsive to incoming pain signals (Cells, 2025). This creates a vicious cycle of hypersensitivity in which even mild stimuli trigger intense pain. The interplay between peripheral and central processes is central to the pathogenesis of IBS, interstitial cystitis, and endometriosis-associated chronic pain.

4.4 Neuroendocrine Regulation

Estrogen directly modulates pain processing, immune function, and mucosal barrier integrity across pelvic organs. Estrogen decline during the late luteal phase triggers not only menstrual pain but also increased bladder sensitivity and bowel symptoms in susceptible women, reflecting the hormonal regulation of cross-organ sensitization. Progesterone has anti-inflammatory and pain-modulatory effects; low progesterone relative to estrogen (a hallmark of estrogen dominance) removes this protective modulation. HPA axis dysregulation from chronic pelvic pain stress produces cortisol abnormalities that impair inflammatory regulation and pain inhibition (Heim et al., Psychoneuroendocrinology, 2000). Chronic pelvic pain is strongly associated with prior physical or emotional trauma, supporting a functional somatic pain syndrome model in which the HPA axis, autonomic nervous system, and immune system are dysregulated by traumatic stress.

4.5 Microbiome and Mucosal Immunity

Beyond the estrobolome, gut dysbiosis directly impacts pelvic pain through multiple mechanisms. Altered tryptophan metabolism from dysbiosis reduces serotonin availability, affecting both gut motility (contributing to IBS symptoms) and descending pain inhibition in the spinal cord. Reduced short-chain fatty acid production weakens intestinal barrier function and reduces anti-inflammatory signaling. Altered microbiome composition has been demonstrated in women with endometriosis, with decreased Lactobacillus and Bifidobacterium and increased pathogenic species (Frontiers in Microbiology, 2025). The reproductive tract harbors its own microbiome that interacts dynamically with gut microbial populations through immune, neural, endocrine, and metabolic axes, forming the gut-endometrial axis (PMC, 2025).

4.6 Structural Domain: Pelvic Floor and Myofascial Pain

Pelvic floor dysfunction — hypertonicity, myofascial trigger points, and impaired coordination of the levator ani and obturator internus muscles — is both a consequence and a perpetuator of chronic pelvic pain. Myofascial trigger points develop secondary to visceral disease in approximately 90% of cases, meaning that the endometriotic lesion or the inflamed bladder creates myofascial pain through viscerosomatic reflexes (PMC, 2015). Once formed, myofascial trigger points become self-sustaining sources of nociception that can maintain pain and sensitization even after the visceral pathology has been treated. Active trigger points reduce pain thresholds, enhance visceral and referred pain, and further sensitize the nervous system. The pelvic floor is the structural domain where visceral, somatic, and central sensitization converge.

5. Inter-Domain Cascade Mechanics

5.1 The Estrobolome-Endometriosis-Immune Cascade

Gut dysbiosis increases β-glucuronidase activity, enhancing estrogen reabsorption and producing estrogen dominance. Elevated circulating estrogen stimulates endometriotic lesion growth and proliferation. Simultaneously, gut dysbiosis drives LPS translocation through a compromised intestinal barrier. LPS activates TLR4 on peritoneal macrophages, triggering NF-κB-mediated inflammation and impairing the macrophages’ ability to phagocytose and clear ectopic endometrial tissue (Front Cell Infect Microbiol, 2024). The surviving endometrial implants generate their own neurogenic inflammation through substance P and CGRP release, sensitizing pelvic afferents and promoting cross-organ sensitization to the bladder and colon. Hormonal suppression with oral contraceptives or GnRH agonists reduces estrogen but does not repair the gut barrier, normalize the estrobolome, or reverse the immune dysfunction allowing lesion persistence. This explains why endometriosis recurs after hormonal treatment discontinuation and why pain persists in many women after surgical excision: the upstream gut-estrogen-immune cascade remains active.

5.2 The Cross-Organ Sensitization Cascade

Chronic nociceptive input from endometriotic lesions sensitizes visceral afferents entering the spinal cord at segments T10–L1 and S2–S4. Through viscerosomatic convergence, these sensitized spinal neurons also process input from the bladder and colon. The sensitized spinal cord amplifies signals from the bladder (producing IC symptoms) and the colon (producing IBS symptoms) even when these organs have no primary pathology. The cross-organ sensitization then becomes bidirectional: bladder inflammation further sensitizes the uterine pathway, and colonic dysfunction amplifies bladder sensitivity. This creates a self-reinforcing pelvic pain network in which removing one nociceptive source (e.g., excising endometriotic lesions) does not quiet the network because the other organs remain sensitized and continue to feed the spinal amplification. Treating the endometriosis without treating the bladder and bowel produces incomplete relief because the cross-organ sensitization maintains the central sensitized state.

5.3 The Myofascial-Visceral Perpetuation Cascade

Sustained visceral nociception generates segmentally referred myofascial trigger points in the abdominal wall, pelvic floor, piriformis, and hip adductors through viscerosomatic reflexes. These trigger points become self-sustaining pain generators that maintain central sensitization even after the visceral source has been addressed. The trigger points also feed back into the visceral pathways through somatovisceral convergence, worsening organ-specific symptoms. A patient may undergo successful laparoscopic excision of endometriosis, but if the myofascial trigger points in the pelvic floor and abdominal wall are not addressed, they continue to generate nociceptive input that maintains the sensitized state and prevents pain resolution. Pelvic floor physical therapy addresses this structural domain, but it cannot resolve the visceral inflammation, the hormonal dysregulation, or the gut barrier dysfunction that created the trigger points.

5.4 The Hormonal-Immune-Gut Feedback Loop

Estrogen dominance from the estrobolome promotes inflammation. Chronic inflammation activates the HPA axis, producing cortisol dysregulation that further impairs immune function and mucosal barrier integrity. Stress-related cortisol abnormalities alter gut permeability, worsening the dysbiosis that drives estrogen dominance. The metabolic consequences of chronic pain — deconditioning, weight gain, insulin resistance — further amplify inflammation through NF-κB activation and adipokine production. Each domain feeds the others in a self-perpetuating cycle that accelerates with time, explaining why chronic pelvic pain typically worsens over years despite multiple specialist interventions: the interventions address downstream organ manifestations without interrupting the upstream biological loop.

6. The Limitations of Organ-Specific Treatment

The treatment paradigm for chronic pelvic pain is defined by organ-specific management delivered by separate specialties. Each intervention targets one component of the multi-domain problem.

Endometriosis: Hormonal suppression (oral contraceptives, GnRH agonists, progestins) reduces estrogen stimulation of lesions but produces side effects including bone loss, menopausal symptoms, mood changes, and metabolic effects. Laparoscopic excision removes visible lesions but does not address microscopic disease, does not reverse central sensitization, and has recurrence rates of 40–50% within 5 years. Neither approach addresses gut dysbiosis, the estrobolome, or immune dysfunction.

Interstitial cystitis: No cure exists. Bladder instillations, pentosan polysulfate sodium, amitriptyline, and dietary modification manage symptoms. These treatments target the bladder mucosa without addressing the systemic mucosal barrier dysfunction, the cross-organ sensitization from other pelvic sources, or the central sensitization maintaining visceral hyperalgesia.

Irritable bowel syndrome: Antispasmodics, low-FODMAP diet, SSRIs/SNRIs, and gut-directed psychological therapy manage symptoms. These do not address intestinal permeability, the estrobolome, or the cross-sensitization with bladder and uterine afferents.

Chronic pelvic pain: Pain management offers gabapentinoids, antidepressants, opioids, nerve blocks, and neuromodulation. These target the pain signal without modifying the visceral inflammation, hormonal dysregulation, gut barrier dysfunction, or immune dysfunction generating the signal.

The consistent pattern across all treatments is partial, temporary, or variable response — the signature of a multi-domain disorder receiving single-domain interventions. Each specialist’s treatment helps some aspect of the problem. No specialist addresses the shared upstream biology connecting all three organs.

7. Clinical Scenarios: Individualized Domain Assessment

The following composite clinical scenarios illustrate how cellular systems theory guides individualized assessment and intervention for pelvic and abdominal pain. All laboratory values represent plausible clinical findings.

7.1 Patient A: Estrobolome-Driven Endometriosis with Cross-Organ Sensitization

Presentation: 34-year-old woman with 8-year history of progressively worsening pelvic pain. Laparoscopically confirmed endometriosis (Stage III) 4 years ago with excision providing 14 months of improvement followed by gradual recurrence. Now reports cyclical pelvic pain (8/10 during menses), chronic baseline pelvic ache (5/10), bladder urgency and suprapubic pressure, bloating with alternating constipation and diarrhea, and dyspareunia. Currently on oral contraceptive continuously (no placebo week). Previous trials of GnRH agonist (bone density concerns), gabapentin (cognitive fog), and amitriptyline (weight gain, constipation). Food sensitivities to dairy and gluten reported. Anxiety 6/10. Sleep 5 hours per night.

Domain Assessment — Laboratory Findings: Fasting insulin 13 µIU/mL (mildly elevated). HbA1c 5.4% (normal). hs-CRP 3.8 mg/L (elevated despite hormonal suppression). Estradiol 42 pg/mL (elevated for continuous OCP use — suggesting incomplete suppression or estrobolome-driven recirculation). Progesterone low relative to estradiol. Elevated evening cortisol. Positive SIBO breath test. Elevated zonulin. Microbiome analysis showing reduced Lactobacillus and Bifidobacterium diversity with elevated β-glucuronidase-producing species. Vitamin D 21 ng/mL (suboptimal). Omega-3 index 2.8% (low).

Domain Interpretation: This patient demonstrates the estrobolome-endometriosis-immune cascade with cross-organ sensitization. Despite continuous OCP use, estradiol remains elevated, suggesting the estrobolome is recycling estrogen through increased β-glucuronidase activity, partially overriding hormonal suppression. SIBO and elevated zonulin confirm gut barrier dysfunction driving LPS-mediated inflammation (hs-CRP elevated despite hormonal therapy). Reduced Lactobacillus and Bifidobacterium with elevated β-glucuronidase-producing species confirm estrobolome dysbiosis. Bladder and bowel symptoms reflect cross-organ sensitization rather than primary bladder or bowel disease. The IBS symptoms and bladder urgency are downstream manifestations of the same pelvic neural sensitization driven by endometriotic nociception and amplified by systemic inflammation. Amitriptyline worsened constipation, potentially exacerbating the gut dysbiosis. Gabapentin addressed one pain pathway without modifying any upstream domain.

Individualized Protocol: SIBO treatment per established protocols. Oral BPC-157 (250–500 µg twice daily) for gut barrier restoration and nitric oxide restoration (Gwyer et al., Cell and Tissue Research, 2019). KPV (200–400 µg orally twice daily) targeting NF-κB inhibition at the gut mucosal level. Elimination dietary protocol (gluten and dairy per sensitivities). Probiotic protocol with Lactobacillus and Bifidobacterium strains to modulate estrobolome and reduce β-glucuronidase activity. Vitamin D repletion. Omega-3 repletion. Selank (250–500 µg SC two to three times daily) for HPA axis modulation and anxiety (Zozulia et al., 2008). DSIP (100–200 µg SC at bedtime) for sleep restoration. Pelvic floor physical therapy for myofascial component. Continue OCP during gut optimization, with reassessment of estradiol, zonulin, hs-CRP, and estrobolome composition at 12 weeks. Medical cannabis evaluation (mythcdr.com, $150) for adjunctive pain modulation.

7.2 Patient B: Visceral-Myofascial Chronic Pelvic Pain in a Man

Presentation: 46-year-old man with 3-year history of chronic pelvic pain diagnosed as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Reports perineal aching, urinary hesitancy, post-void discomfort, and low back pain radiating to the inner thighs. Multiple courses of antibiotics without improvement. Reports food sensitivities, bloating, and stress-related symptom flares. Pain 6/10. Anxiety significant. Sleep disrupted by nocturia and pain.

Domain Assessment — Laboratory Findings: Fasting insulin 15 µIU/mL (mildly elevated). hs-CRP 2.4 mg/L (mildly elevated). Total testosterone 310 ng/dL (low-normal). Elevated evening cortisol. Positive SIBO breath test. Elevated zonulin. Vitamin D 24 ng/mL (suboptimal). Prostate exam unremarkable. Urinalysis normal. Prior urine cultures negative.

Domain Interpretation: This patient demonstrates the visceral-myofascial perpetuation cascade. Negative cultures and failed antibiotics confirm this is not an infectious prostatitis but a visceral pain syndrome with pelvic floor myofascial dysfunction. The perineal aching, urinary symptoms, and referred pain to the inner thighs are consistent with viscerosomatic convergence and myofascial trigger points in the pelvic floor. SIBO and elevated zonulin confirm gut barrier dysfunction feeding systemic inflammation and potentially driving visceral sensitization. Elevated evening cortisol reflects HPA axis overactivation from chronic pain stress. This is fundamentally the same gut-immune-sensitization cascade documented in female pelvic pain, manifesting through male pelvic anatomy.

Individualized Protocol: SIBO treatment. Oral BPC-157 (250–500 µg twice daily) for gut barrier restoration (Gwyer et al., 2019). KPV (200–400 µg orally twice daily) for NF-κB inhibition. Pelvic floor physical therapy with internal myofascial release for trigger point deactivation. Elimination dietary protocol. Selank (250–500 µg SC two to three times daily) for anxiety and HPA axis modulation (Zozulia et al., 2008). Vitamin D optimization. Testosterone optimization if symptomatic. DSIP at bedtime for sleep. Reassessment at 12 weeks.

7.3 Patient C: Post-Hysterectomy Persistent Pelvic Pain

Presentation: 49-year-old woman who underwent total hysterectomy with bilateral salpingo-oophorectomy 2 years ago for endometriosis and pelvic pain. Pain initially improved for 6 months, then gradually returned to pre-surgical levels. Reports persistent bilateral pelvic aching, bladder pressure, bowel sensitivity, and allodynia of the lower abdominal wall. On estrogen patch 0.05 mg. Reports fatigue, weight gain of 18 pounds since surgery, and brain fog. Pain 7/10. Has been told by her gynecologist that there is no remaining endometriosis to treat.

Domain Assessment — Laboratory Findings: Fasting insulin 22 µIU/mL (elevated). HbA1c 6.0%. hs-CRP 4.6 mg/L (elevated). Estradiol 35 pg/mL (appropriate for patch). Elevated zonulin. Microbiome analysis showing reduced diversity. Vitamin D 18 ng/mL (deficient). Omega-3 index 2.2% (critically low). Organic acids showing mitochondrial dysfunction markers. Elevated evening cortisol. Thyroid: TSH 4.6 with low-normal free T3.

Domain Interpretation: This patient demonstrates why hysterectomy failed to resolve her pain. The surgery removed the uterus and ovaries but did not address the central sensitization (evidenced by lower abdominal allodynia), the gut barrier dysfunction (elevated zonulin, reduced diversity), the metabolic syndrome developing post-surgically (insulin resistance, weight gain), the subclinical hypothyroidism, or the ongoing cross-organ sensitization involving the bladder and bowel. The surgically induced menopause, while eliminating cyclical endometrial stimulation, produced metabolic deterioration. Post-surgical deconditioning and weight gain worsened insulin resistance. The NF-κB pathway is active from both gut-derived inflammation and metabolic-inflammatory amplification. Up to 79% of women with persistent pain after hysterectomy for pelvic pain have interstitial cystitis that was never diagnosed (PMC, 2007). Her bladder was never evaluated because the gynecologist focused on the uterus.

Individualized Protocol: Gut barrier restoration: BPC-157 (250–500 µg orally twice daily), KPV (200–400 µg orally twice daily). Metabolic optimization: anti-inflammatory dietary protocol, graded exercise targeting insulin sensitization. MOTS-c (5–10 mg SC three times weekly) for AMPK activation and insulin sensitization (Lee et al., Cell Metabolism, 2015). Thyroid optimization. Vitamin D repletion. Omega-3 repletion. IC evaluation with urology: potassium sensitivity test, cystoscopy if indicated. Pelvic floor PT for myofascial component and allodynia desensitization. SS-31 (5–10 mg SC daily) for mitochondrial support (Szeto, 2014). Selank for HPA axis modulation (Zozulia et al., 2008). DSIP at bedtime for sleep. Reassessment at 12 weeks. If IC confirmed, VIP (25–50 µg SC daily, titrating slowly) for mucosal immune modulation and mast cell stabilization.

8. Emerging Peptide Therapeutics: Domain-Targeted Intervention

Peptide therapeutics offer potential for domain-targeted intervention in pelvic and abdominal pain. No RCTs of these peptides for pelvic pain as primary indications have been published; evidence is extrapolated from mechanism-of-action studies.

BPC-157 restores gut barrier integrity through epithelial tight junction repair, restores nitric oxide production, and reduces intestinal inflammation (Gwyer et al., Cell and Tissue Research, 2019). Its primary relevance to pelvic pain is targeting the upstream gut barrier dysfunction that drives LPS translocation, estrobolome dysregulation, and systemic NF-κB activation. Orally at 250–500 µg twice daily. Not FDA-approved.

KPV directly inhibits NF-κB without suppressing overall immune function, concentrating preferentially in gastrointestinal mucosa. Targets the LPS-TLR4-NF-κB inflammatory amplification pathway common to endometriosis, IC, and IBS through shared inflammatory mechanisms. Orally at 200–400 µg twice daily. Not FDA-approved.

VIP (vasoactive intestinal peptide) induces regulatory T cells, stabilizes mast cells, modulates autonomic function, and supports mucosal immunity. Particularly relevant for interstitial cystitis, which involves mast cell activation in the bladder submucosa and mucosal barrier dysfunction. Also relevant for autonomic-mediated pelvic pain. Subcutaneously at 25–50 µg one to two times daily. Not FDA-approved.

TB-500 promotes anti-fibrotic tissue remodeling (Malinda et al., 1999). Relevant for endometriotic adhesions and pelvic scarring that generate ongoing nociceptive input and contribute to myofascial trigger point formation. Subcutaneously at 750 µg to 1.5 mg twice weekly. Not FDA-approved.

Selank modulates GABA for anxiolysis without sedation (Zozulia et al., 2008). Addresses the HPA axis dysregulation and anxiety component of chronic pelvic pain, which is strongly associated with prior trauma and stress-mediated pathophysiology. Subcutaneously at 250–500 µg two to three times daily. Not FDA-approved in the US.

MOTS-c activates AMPK for insulin sensitization and anti-inflammatory effects (Lee et al., 2015). Relevant when metabolic syndrome coexists with pelvic pain, particularly in post-surgical patients with weight gain and insulin resistance. Subcutaneously at 5–10 mg three times weekly. Not FDA-approved.

Thymosin Alpha-1 rebalances immune function by restoring Th1/Th2 balance and regulatory T-cell activity. Relevant for the immune dysregulation documented in endometriosis, which exhibits autoimmune-like features with impaired immune clearance of ectopic tissue. Subcutaneously at 1.6 mg two to three times weekly. Not FDA-approved in the US.

Peptide protocols are individualized based on domain assessment findings. The clinical scenarios in Section 7 illustrate how different pelvic pain presentations require different peptide approaches.

9. Discussion

The evidence reviewed in this paper supports three propositions. First, chronic pelvic and abdominal pain involves shared biological domain dysfunction across multiple organs rather than coincidental co-occurrence of separate organ diseases. Viscerosomatic convergence provides the neuroanatomical basis for cross-organ pain referral. Cross-organ sensitization has been experimentally demonstrated between the bladder, colon, and uterus. The estrobolome connects gut dysbiosis to estrogen dominance and endometriosis progression. The LPS-TLR4-NF-κB pathway drives inflammation simultaneously across multiple pelvic organs. These shared mechanisms explain the clinical triad of endometriosis, interstitial cystitis, and IBS at rates exceeding chance.

Second, the organ-specific treatment paradigm — gynecology for the uterus, urology for the bladder, gastroenterology for the bowel, pain management for the pain signal — produces partial, temporary, and variable treatment response because each specialty addresses one downstream organ manifestation without evaluating the shared upstream biology. Endometriosis recurs after excision because the estrobolome continues to drive estrogen dominance. IC persists because the mucosal barrier dysfunction is systemic, not bladder-specific. IBS continues because the gut dysbiosis driving visceral sensitization is never comprehensively addressed. Pain returns after hysterectomy because central sensitization, cross-organ sensitization, and myofascial trigger points were never evaluated.

Third, the multi-specialty fragmentation of pelvic pain care is itself a barrier to effective treatment. No single specialist evaluates the gut microbiome, the estrobolome, the intestinal permeability, the metabolic status, the hormonal balance, the pelvic floor myofascial component, and the central sensitization state in the same patient. Cellular systems theory provides the integrative framework for this comprehensive assessment.

Limitations include the narrative methodology, the preclinical basis of most peptide evidence, the absence of randomized controlled trials testing multi-domain interventions in pelvic pain populations, and the complexity of distinguishing primary from secondary visceral pathology. Prospective trials comparing integrated domain-targeted protocols with standard organ-specific care are needed.

10. Conclusion

Chronic pelvic and abdominal pain is fragmented across medical specialties as though the uterus, bladder, and bowel are separate biological systems. They are not. They share neural pathways through viscerosomatic convergence, share mucosal immune regulation, share hormonal responsiveness, and share an upstream driver in the gut-estrogen-immune axis that no single specialty evaluates. The estrobolome connects gut dysbiosis to estrogen dominance. LPS translocation connects gut barrier failure to multi-organ pelvic inflammation. Cross-organ sensitization connects endometriosis to interstitial cystitis to irritable bowel syndrome through shared spinal cord processing. Cellular systems theory provides a framework for understanding why the gynecologist, the urologist, and the gastroenterologist each provide partial relief but none provides resolution — and for directing treatment toward the shared biological domains that connect what conventional medicine has artificially separated.

Author Information

Ty Thomas, MD, is CEO and Medical Director of Alabama Pain Physicians, a board-certified interventional pain practice in Birmingham and Bessemer, Alabama. Dr. Thomas is board-certified in Physical Medicine and Rehabilitation with additional certification in Venous and Lymphatic Medicine. Alabama Pain Physicians integrates functional laboratory assessment and metabolic optimization with conventional pain management. Contact: 205.332.3160. BamaPain.com. For medical cannabis evaluation: mythcdr.com. For opioid recovery services: TheRenewClinic.com.

Disclosures: The author reports no external conflicts of interest relevant to this manuscript. Alabama Pain Physicians offers the laboratory panels and peptide therapeutics described in this review as clinical services. No external funding was received for this work.

References

1. Dydyk AM, Singh C, Gupta N. Chronic pelvic pain. StatPearls. 2025.

2. Butrick CW. Patients with chronic pelvic pain: endometriosis or interstitial cystitis/painful bladder syndrome? JSLS. 2007;11(2):182-189.

3. Endometriosis-associated chronic pelvic pain. PMC. 2024.

4. Research on central sensitization of endometriosis-associated pain. J Pain Res. 2023.

5. Molecular mechanisms and pathways in visceral pain. Cells. 2025;14(15):1146.

6. Association of chronic pelvic pain and endometriosis with signs of sensitization and myofascial pain. PMC. 2015.

7. Relating chronic pelvic pain and endometriosis to signs of sensitization and myofascial pain and dysfunction. PMC. 2017.

8. Demonstration of cutaneous allodynia in association with chronic pelvic pain. PubMed. 2009.

9. Pain in endometriosis. Frontiers in Cellular Neuroscience. 2020;14:590823.

10. Gut and reproductive tract microbiota: insights into the pathogenesis of endometriosis. PMC. 2023.

11. Unraveling the microbial puzzle: exploring the intricate role of gut microbiota in endometriosis pathogenesis. Front Cell Infect Microbiol. 2024;14:1328419.

12. Role of the gut microbiota in the pathogenesis of endometriosis: a review. Frontiers in Microbiology. 2024;15:1363455.

13. Association between endometriosis and gut microbiota: systematic review and meta-analysis. Frontiers in Microbiology. 2025.

14. The role of the gut microbiota in female reproductive and gynecological health. PMC. 2025.

15. The gut microbiota: a puppet master in the pathogenesis of endometriosis? PubMed. 2016.

16. The multifactorial pathogenesis of endometriosis: hormonal, immune, and microbiome aspects. Medicina. 2025;61(5):811.

17. Camilleri M. Leaky gut: mechanisms and implications. Gut. 2019;68(8):1516-1526.

18. Niederberger E, Geisslinger G. The IKK-NF-κB pathway. FASEB Journal. 2008;22(10):3432-3442.

19. Woolf CJ. Central sensitization. Pain. 2011;152(3 Suppl):S2-S15.

20. Watkins LR, Maier SF. Immune and glial cells in pathological pain. Physiological Reviews. 2002;82(4):981-1011.

21. Heim C, et al. Hypocortisolism in stress-related disorders. Psychoneuroendocrinology. 2000;25(1):1-35.

22. Finan PH, et al. Sleep and pain association. Journal of Pain. 2013;14(12):1539-1552.

23. Lee C, et al. MOTS-c promotes metabolic homeostasis. Cell Metabolism. 2015;21(3):443-454.

24. Gwyer D, et al. BPC 157 in musculoskeletal healing. Cell and Tissue Research. 2019;377(2):153-159.

25. Malinda KM, et al. Thymosin beta4 in wound healing. J Invest Dermatol. 1999;113(3):364-368.

26. Zozulia AA, et al. Selank in generalized anxiety. Zh Nevrol Psikhiatr. 2008;108(4):38-48.

27. Szeto HH. Cardiolipin-protective compound. Br J Pharmacol. 2014;171(8):2029-2050.

28. Minerbi A, et al. Altered microbiome in fibromyalgia. Pain. 2019;160(11):2589-2602.

29. Choy EH. Sleep in pain and fibromyalgia. Nature Reviews Rheumatology. 2015;11(9):513-520.

30. Helde-Frankling M, et al. Vitamin D in pain management. IJMS. 2017;18(10):2170.

© 2026 Alabama Pain Physicians. All rights reserved.